SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

31 Jan 2022 Evaluate
The total revenue stands at Rs. 44.33 millions for the December 2021 quarter. The mentioned figure indicates an increase of about 192.99% as against Rs. 15.13 millions during  the year-ago period.The Net Loss for the quarter ended December 2021 is Rs. -82.19 millions as compared to Net Loss of Rs. -81.47 millions of corresponding quarter ended December 2020 Operating profit Margin for the quarter ended December 2021 improved to -68.67% as compared to -87.46% of corresponding quarter ended December 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 44.33 15.13 192.99 76.23 119.22 -36.06 134.78 144.15 -6.50
Other Income 1.41 16.24 -91.32 51.99 64.30 -19.14 77.54 140.36 -44.76
PBIDT -68.67 -87.46 -21.48 -239.72 -155.98 53.69 -227.93 -212.80 7.11
Interest 1.30 1.67 -22.16 4.33 6.15 -29.59 8.15 4.87 67.35
PBDT -69.97 -89.13 -21.50 -244.05 -162.13 50.53 -236.08 -217.67 8.46
Depreciation 12.22 11.41 7.10 32.90 32.81 0.27 43.46 41.69 4.25
PBT -82.19 -100.54 -18.25 -276.95 -194.94 42.07 -279.54 -259.36 7.78
TAX 0.00 -19.07 0.00 0.00 -53.69 0.00 -53.23 -121.83 -56.31
Deferred Tax 0.00 -19.07 0.00 0.00 -53.69 0.00 -53.23 -141.55 -62.39
PAT -82.19 -81.47 0.88 -276.95 -141.25 96.07 -226.31 -137.53 64.55
Equity 127.28 127.28 0.00 127.28 127.28 0.00 127.28 127.28 0.00
PBIDTM(%) -154.91 -578.06 -73.20 -314.47 -130.83 140.36 -169.11 -147.62 14.56

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×